Cytonics is developing an exciting product that meets a significant need in a growing market ($180b currently). The company has a strong executive team and board of advisors, and EPO believes their business model closely matches their core competencies. Preclinical results indicate signs of safety & efficacy, which paves the way to submission for Phase 1 of FDA approval.
1. 1. The potential market size for CYT-108
2. The risk associated with the FDA trial process
Developing proprietary and innovative biologic therapies for osteoarthritis.
Cytonics is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Cytonics: https://www.seedinvest.com/cytonics